Davita stock

DVA · NYSE · USD

Compare Davita
$161.03Change from previous close: +3.00%Absolute change: +$4.69

Close · November 20, 2026

Price history

+39.60% over the period

1 year: from $115.35 (November 20, 2025) to $161.03 (November 20, 2026), +39.60%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 20, 2026$161.03
October 30, 2026$187.50
September 30, 2026$174.92
August 31, 2026$176.01
July 31, 2026$240.09
June 30, 2026$222.48
May 29, 2026$194.36
April 30, 2026$155.14
March 31, 2026$153.69
February 27, 2026$156.30
January 30, 2026$109.34
December 31, 2025$113.61
November 28, 2025$119.68
November 20, 2025$115.35

At a glance

  • The company

    Provides kidney dialysis services and related lab services for chronic kidney failure patients in the United States

  • Latest results

    Quarter to September 30, 2026 · EPS $3.82 (estimate $3.55)

TickerLandia's take on Davita

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$101.00
52-wk high$247.49

−34.93% from the 52-week high

Analysts · 8 analysts

Average target$222.29+38.04% vs. price

Buy 3 · Hold 3 · Sell 2 · Buy

TickerLandia Fingerprint: Davita

Compared with similar companies: low price and low financial strength.

Financials and price compared with 19 companies in the medical care facilities industry, worldwide. Momentum and risk compared with 888 North American stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Davita is pricier than in the past and cheaper than similar companies

On the latest fiscal year's earnings (2025), Davita's P/E today is 16.4, above the median of its last 10 fiscal years (14.2; between 11.5 and 55.9 from 2016 to 2025). Davita's P/E (trailing 12 months): 12.2, −28% against the median of a group of 11 similar companies (16.9).

P/E compared with its history

Compared with 11 similar companies

Davita's metrics compared with similar companies
MetricDavitaPosition in the groupBand
P/E (trailing 12 months)12.2Low
Forward P/E9.52Low
Operating margin15.2%Middle
ROE96.8%High
Debt/equity11.9High

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Davita. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$3.58B

Latest quarter · Q3 2026

Net income

$222.93M

Latest quarter · Q3 2026

Quarterly net margin

6.2%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
$10.13B
P/E
12.2
EPS
$13.21
Volume
730.12K
Daily trading
€141.98M
Dividend yield
0.00%

How Davita is changing

All results
  • Revenue grew 3.4% a year on average over the last 5 years

  • Operating margin rose from 11.5% to 15.0%

  • Profits turn into cash: free cash flow equal to 180% of net income

Returns

Davita returns

$1,000 invested in Davita 5 years ago, on November 22, 2021, would be worth $1,568 today: +56.84% in total, +9.43% per year. This is the price return only: dividends are excluded.

PeriodDavitaS&P 500$1,000 becomes
1 month−8.17%−10.40%$918
6 months−18.20%−7.03%$818
Year to date+41.74%+0.95%$1,417
1 year+39.60%+5.68%$1,396
3 years+65.11%+51.96%$1,651
5 years+56.84%+47.57%$1,568
10 years+156.21%+214.37%$2,562

Over the last 6 months it has done better than 11% of the stocks in the Healthcare sector.

Price only, without dividends. Calculate your investment

The chart in detail

Davita: technical analysis

Davita shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 33.2% below its all-time closing high ($240.96, July 29, 2026).

Trend
No clear trend
RSI (14 sessions)
36
Between 30 and 70
vs 200-session average
−11.43%

Active signals

  • Death cross: the 50-session average has crossed below the 200-session average.

    since November 19, 2026

Support and resistance

Price areas where Davita has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance$196.36+21.94%2 touches, last on October 29, 2026
  2. Resistance$191.39+18.85%2 touches, last on October 20, 2026
  3. Resistance$171.90+6.75%4 touches, last on October 30, 2026
  4. Last price$161.03
  5. Support$156.54−2.79%5 touches, last on April 23, 2026
  6. Support$145.58−9.59%5 touches, last on May 5, 2026
  7. Support$122.44−23.97%2 touches, last on December 11, 2025

Volatility and risk

Over the last year it has moved little with the S&P 500.

Beta (1 year) vs S&P 500
−0.05
Volatility (60 sessions, annualised)
41.7%
Largest fall in the last year
−35.12%

Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Davita: seasonality

Average monthly price change over 31 years

+0.3%Jan−0.8%Feb+2.0%Mar+2.5%Apr+2.7%May+4.9%Jun−0.5%Jul−1.4%Aug+1.6%Sep+0.4%Oct+5.1%Nov+4.0%Dec

Over the last 31 years, the strongest month for Davita has been November: +5.09% on average, positive in 19 years out of 31. The weakest has been August: −1.41% on average, positive in 13 years out of 31.

Show chart data
MonthAverageMedianPositive years
January+0.27%+1.03%16 of 31
February−0.78%−0.16%15 of 31
March+1.96%+0.30%17 of 31
April+2.55%+0.94%20 of 31
May+2.68%+2.47%19 of 31
June+4.85%+2.41%19 of 31
July−0.51%+0.21%17 of 31
August−1.41%−1.17%13 of 31
September+1.64%+1.24%17 of 31
October+0.40%+0.70%16 of 31
November+5.09%+1.32%19 of 31
December+4.05%+2.15%18 of 31

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Davita and its competitors

Based in Denver, Colorado, DaVita Inc. has existed since 1994 and works in dialysis. Its core business is treating patients whose kidneys have lost their function, delivered mainly through outpatient dialysis centers in the United States, with hospital inpatient and home-based hemodialysis also offered. Alongside these treatments, the group runs clinical laboratories serving dialysis patients, provides management and administrative services to outpatient dialysis centers, and offers integrated care, disease management and physician services. It also holds a transplant software business and conducts clinical research programs.

Headquarters
Denver, United States
Employees
78,000
Founded
1994
Chief executive
Javier Rodriguez
Davita and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
DavitaDVA$10.13B15.2%12.2−18.20%
Ensign GroupENSG$10.29B8.8%26.2−1.09%
Universal Health ServicesUHS$10.34B10.9%7.51+9.20%
Encompass HealthEHC$13.11B18.4%21.4+26.10%
Tenet HealthcareTHC$20.95B19.1%7.68+40.44%
HCA HealthcareHCA$99.34B15.3%15.8+19.89%

Same industry or related industries, similar size. Compare Davita with its competitors · Full profile